Savara Inc cotiza a 4.84 USD y tiene una capitalización bursátil de $992M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar …
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-0.13 | $-0.14 |
| Estimado | $-0.17 | $-0.15 | $-0.12 | $-0.13 |
| Sorpresa | — | — | -8.3% | -7.7% |
| Métrica | SVRA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -58.5% | -40.4% | -18.1% |
| ROA | -46.9% | -32.0% | -14.9% |
| Current Ratio | 11.85 | 2.84 | +9.01 |
| Debt / Equity | 0.15 | 0.28 | -0.13 |